FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to internal diseases, gastroenterology, cardiology and clinical laboratory diagnostics, and can be used for prediction of risk of formation of erosion-ulcer lesions of gastroduodenal zone in patients with arterial hypertension (AH) by laboratory blood analysis. Patient with AH in blood is examined for thrombocyte count, leukocyte count, glucose concentration, cholesterol level, content of monocyte chemotactic protein-1 and endothelin-1. Predicted risk of formation of erosion-ulcer lesions of the gastroduodenal zone is calculated by formula: Y=0.515+0.001⋅X1+0.547⋅X2-0.002⋅X3+0.044⋅X4-0.107⋅X5-0.048⋅X6, where Y – predicted risk of formation of erosive-ulcerous gastroduodenal lesions in patients with AH, X1 – concentration of monocyte chemotactic protein-1 (pg/ml), X2 – level of endothelin-1 (fmole/ml), X3 – amount of thrombocytes (109/l), X4 – number of leukocytes (109/l), X5 – concentration of glucose (mmol/l), X6 is cholesterol concentration (mmol/l). If Y is equal to or greater than 1, a risk of formation of erosion-ulcerous gastroduodenal lesions in the patients with AH is predicted. If Y is less than 1, there is no risk of formation of erosion-ulcerous gastroduodenal lesions in AH patients.EFFECT: method provides the possibility of increasing the prediction accuracy of the risk of formation of erosion-ulcerous gastroduodenal lesions in the patients with arterial hypertension by using a quantitative prediction criterion based on laboratory blood test results.1 cl, 3 exИзобретение относится к медицине, а именно к внутренним болезням, гастроэнтерологии, кардиологии и клинической лабораторной диагностике, и может быть использовано для прогнозирования риска формирования эрозивно-язвенных поражений гастродуоденальной зоны у пациентов с артериальной гипертензией (АГ) с помощью лабораторного анализа крови. У пациента с АГ в крови определяют количество тромбоцитов, лейкоцитов, концентрацию глюкозы, уровень
